TY - JOUR
T1 - Ocular stem cell research from basic science to clinical application
T2 - A report from zhongshan ophthalmic center ocular stem cell symposium
AU - Ouyang, Hong
AU - Goldberg, Jeffrey L.
AU - Chen, Shuyi
AU - Li, Wei
AU - Xu, Guo Tong
AU - Li, Wei
AU - Zhang, Kang
AU - Nussenblatt, Robert B.
AU - Liu, Yizhi
AU - Xie, Ting
AU - Chan, Chi Chao
AU - Zack, Donald J.
N1 - Publisher Copyright:
© 2016 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2016/3/22
Y1 - 2016/3/22
N2 - Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt’s disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.
AB - Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt’s disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.
KW - Age-related macular degeneration
KW - Eye diseases
KW - Glaucoma
KW - Limbal stem cell deficiency
KW - Regenerative medicine
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=85006707340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006707340&partnerID=8YFLogxK
U2 - 10.3390/ijms17030415
DO - 10.3390/ijms17030415
M3 - Article
C2 - 27102165
AN - SCOPUS:85006707340
SN - 1661-6596
VL - 17
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 3
M1 - 415
ER -